HKEX Listing Requirements: Financial Eligibility Tests for Main Board Applicants

The SFC and HKEX published their joint conclusions on proposed listing regime enhancements on 20 December 2024, signalling the most significant overhaul of Main Board financial eligibility tests since the 2018 reforms. Market participants preparing for 2025-2026 listings must now navigate a three-track system — the existing profit test, the market capitalisation/revenue/cash flow test, and the newly recalibrated market capitalisation/revenue test — each with distinct thresholds, disclosure obligations, and sponsor verification requirements. The changes directly affect the 167 companies that submitted A1 applications to HKEX in 2024, of which 54% elected the market capitalisation/revenue test as their primary pathway, according to HKEX’s 2024 annual review of listing applications. For CFOs and company secretaries of pre-IPO companies, understanding the precise mechanics of each test — including the 60-month trading record requirement under Rule 8.05, the 40% market capitalisation threshold for the revenue test, and the enhanced working capital disclosure under the new Chapter 9A — is no longer optional due diligence but a structural prerequisite for any successful Main Board application in the current regulatory environment.

The Three Financial Eligibility Tests Under Rule 8.05

HKEX Main Board Listing Rule 8.05 establishes three alternative financial eligibility tests that applicants must satisfy. The rule operates on an either/or basis — an applicant needs to meet only one test in full, not multiple tests partially. The three tests are the Profit Test, the Market Capitalisation/Revenue/Cash Flow Test, and the Market Capitalisation/Revenue Test. Each test imposes different minimum thresholds for profit, market capitalisation, revenue, and cash flow, depending on the applicant’s business maturity and growth profile.

Profit Test: The Traditional Pathway

The Profit Test under Rule 8.05(1) requires the applicant to demonstrate a profit attributable to shareholders of at least HKD 35 million for the most recent financial year and HKD 45 million in aggregate across the three preceding financial years. This means the minimum aggregate profit over three years is HKD 80 million, with a back-end weighting that requires the most recent year to contribute at least HKD 35 million. The HKEX’s 2023 Guidance Letter GL66-23 clarifies that the profit calculation must exclude any non-recurring or extraordinary items, and the sponsor must confirm in the listing document that the profit trend is sustainable.

The Profit Test remains the most straightforward pathway for established, profitable companies. In 2024, 38% of new Main Board listings used the Profit Test, according to HKEX’s 2024 Market Statistics. The test requires no minimum revenue or market capitalisation threshold, making it particularly suitable for traditional manufacturing, retail, and property companies with consistent earnings records. However, the test imposes a 60-month (five-year) trading record requirement under Rule 8.05(1)(a), which is the longest track record among the three tests. Applicants must also satisfy the management continuity requirement — the same management must have been in place for at least three consecutive financial years — and the ownership continuity requirement — the same controlling shareholder must have held control for at least one financial year.

Market Capitalisation/Revenue/Cash Flow Test: For High-Growth Companies

The Market Capitalisation/Revenue/Cash Flow Test under Rule 8.05(2) requires the applicant to meet three separate thresholds simultaneously. First, the market capitalisation at the time of listing must be at least HKD 4 billion. Second, the revenue for the most recent financial year must be at least HKD 500 million. Third, the aggregate positive cash flow from operating activities across the three preceding financial years must be at least HKD 100 million. All three conditions must be satisfied; failure on any one condition disqualifies the applicant from using this test.

This test was introduced in the 2018 listing regime reforms primarily to accommodate pre-revenue biotech companies and high-growth technology firms that could demonstrate strong cash generation capability but had not yet reached profitability. The HKEX’s 2024 annual review of listing applications shows that 22% of applicants in 2024 elected this test, with the majority being healthcare and technology companies. The sponsor must verify the cash flow figures against audited financial statements and provide a detailed analysis of the sustainability of the positive cash flow trend in the sponsor’s declaration under Rule 3A.03.

Market Capitalisation/Revenue Test: The Newly Recalibrated Pathway

The Market Capitalisation/Revenue Test under Rule 8.05(3) was significantly recalibrated in the December 2024 joint conclusions. The test now requires a minimum market capitalisation of HKD 6 billion at the time of listing — increased from the previous HKD 4 billion threshold — and a minimum revenue of HKD 1 billion for the most recent financial year, up from HKD 500 million. The HKEX stated in the conclusions that the revised thresholds aim to “ensure that only companies with sufficient scale and market recognition can access the Main Board through this pathway.”

This test is designed for large-scale, high-revenue companies that may not yet be profitable or cash flow positive but have demonstrated substantial commercial traction. The 54% of 2024 applicants that elected this test under the old thresholds will now face the higher HKD 6 billion market capitalisation requirement if they have not yet received listing approval before the new rules take effect on 1 July 2025. The sponsor must include in the listing document a detailed discussion of the business model, revenue drivers, and the basis for the market capitalisation valuation, including a comparison with listed peers in the same industry.

Enhanced Disclosure and Sponsor Requirements

The December 2024 reforms introduced new Chapter 9A to the Main Board Listing Rules, which imposes enhanced disclosure obligations on applicants using the Market Capitalisation/Revenue Test and the Market Capitalisation/Revenue/Cash Flow Test. These requirements go beyond the standard disclosure under Chapter 11 and directly affect the content of the prospectus, the sponsor’s work programme, and the due diligence scope.

Working Capital Sufficiency Disclosure Under Chapter 9A

Chapter 9A.03 requires every applicant using a market capitalisation-based test to include in the prospectus a working capital sufficiency statement covering at least 12 months from the date of the prospectus. The statement must be supported by a detailed cash flow forecast prepared by the applicant and reviewed by the sponsor. The HKEX’s 2024 Guidance Letter GL123-24 specifies that the forecast must include sensitivity analysis showing the impact of a 20% decline in revenue and a 20% increase in operating costs on the applicant’s cash position.

This requirement is particularly onerous for pre-revenue biotech companies and early-stage technology firms. The sponsor must confirm in its declaration under Rule 3A.03 that it has conducted independent verification of the key assumptions underlying the cash flow forecast, including customer contracts, supplier agreements, and debt repayment schedules. The HKEX has the discretion to request additional supporting documentation, including bank statements and confirmation letters from the applicant’s principal bankers.

Sponsor Independence and Due Diligence Scope

The SFC’s Code of Conduct for Persons Licensed by or Registered with the Securities and Futures Commission, specifically paragraph 17.6, requires sponsors to conduct due diligence on the applicant’s compliance with the financial eligibility test selected. The sponsor must document in its due diligence work programme the specific verification steps taken for each threshold. For the Profit Test, this includes confirming the exclusion of non-recurring items and verifying the sustainability of the profit trend. For the cash flow test, the sponsor must trace the cash flow figures back to the audited financial statements and confirm that the cash flows are derived from operating activities, not financing or investing activities.

The HKEX’s 2023 enforcement record shows that 12 listing applications were rejected or withdrawn due to sponsor due diligence deficiencies, with 7 of those cases involving incorrect classification of revenue or cash flow items. The SFC issued fines totalling HKD 87 million against three sponsors in 2023 for failures in verifying financial eligibility thresholds, according to the SFC’s 2023-24 Annual Report.

Practical Implications for Pre-IPO Companies

CFOs and company secretaries of pre-IPO companies must align their financial reporting and business planning with the specific test they intend to use. The choice of test affects not only the timing of the listing but also the valuation strategy, the structure of the pre-IPO funding round, and the content of the prospectus.

Timing and Track Record Considerations

The Profit Test requires a 60-month trading record, which means a company must have been in operation for at least five financial years before it can list. The Market Capitalisation/Revenue/Cash Flow Test and the Market Capitalisation/Revenue Test both require a 36-month trading record under Rule 8.05(2)(a) and Rule 8.05(3)(a) respectively. For companies incorporated in the Cayman Islands or Bermuda — the most common listing vehicles for Hong Kong IPOs — the track record period runs from the date of incorporation of the listing vehicle, not the operating company. This creates a structural issue for group reorganisations: the sponsor must confirm that the listing vehicle has been in existence for the required period, or the HKEX may require a waiver under Rule 8.05A.

The HKEX granted 23 waivers under Rule 8.05A in 2024, primarily for companies that had undergone group restructuring within the 36-month period. The waiver application must demonstrate that the business operations have remained substantially the same before and after the restructuring, and that the management and ownership continuity requirements are met.

Valuation and Pre-IPO Funding Implications

The market capitalisation thresholds under the Market Capitalisation/Revenue Test (HKD 6 billion) and the Market Capitalisation/Revenue/Cash Flow Test (HKD 4 billion) directly affect the pricing of pre-IPO funding rounds. A company targeting the Market Capitalisation/Revenue Test must ensure that its pre-IPO valuation supports a listing market capitalisation of at least HKD 6 billion. This typically requires a pre-IPO funding round of at least HKD 1.5 billion to HKD 2 billion to establish the valuation benchmark, assuming a 25% to 33% dilution.

The HKEX’s 2024 Guidance Letter GL112-24 states that the market capitalisation at listing must be supported by independent valuation evidence, including the pricing of the most recent pre-IPO funding round, a comparison with listed peers, and a discounted cash flow analysis. The sponsor must confirm that the valuation is reasonable and that there is no evidence of artificial inflation through circular transactions or related party arrangements.

Key Takeaways for CFOs and Company Secretaries

1. Select the financial eligibility test before commencing the A1 application preparation, as the test determines the required track record period, disclosure scope, and sponsor due diligence programme — switching tests mid-process can delay the application by 6 to 12 months based on HKEX’s 2024 processing timeline data.

2. Ensure that the audited financial statements for the track record period are prepared in accordance with HKFRS or IFRS, with no material qualifications, as the HKEX will reject any application where the auditor’s report contains a disclaimer of opinion or adverse opinion under Rule 8.06.

3. Prepare the working capital sufficiency forecast at least 6 months before the expected A1 submission date, including sensitivity analysis for a 20% revenue decline and a 20% cost increase, as required under Chapter 9A.03 and Guidance Letter GL123-24.

4. Verify that the listing vehicle has been in existence for the required track record period — 60 months for the Profit Test, 36 months for the other tests — and apply for a waiver under Rule 8.05A if a group restructuring has occurred within the period.

5. Engage the sponsor early to conduct a preliminary assessment of which test the company qualifies for, including a review of the revenue recognition policy, the classification of cash flow items, and the valuation basis for the market capitalisation threshold, to avoid last-minute disqualification.